Topical application of a Rho-kinase inhibitor in rats causes penile erection

International Journal of Impotence Research

Volumn 16, Issue 3, 2004, Pages 294-298

  Dai, Y ^a,b   Chitaley, K ^a   Webb, R C ^a   Lewis, R W ^a   Mills, T M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Erectile response; Rat; Rho kinase; RhoA; Topical drug application

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC INNERVATION; CASTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; MALE; NONHUMAN; PENILE BLOOD FLOW; PENILE BLOOD VESSEL; PENIS ERECTION; PENIS GLANS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STIMULATION; TUNICA ALBUGINEA; VASOCONSTRICTION;

ADMINISTRATION, TOPICAL; AMIDES; ANIMALS; BLOOD PRESSURE; ELECTRIC STIMULATION; ENZYME INHIBITORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PENILE ERECTION; PENIS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3042702873     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901171     Document Type: Article

References (27)

1. Pryor JL, Redmon B. New therapies and delivery mechanisms for treatment of erectile dysfunction. Int J Impot Res 2000; 12: S158-S162.
2. Morales A. Developmental status of topical therapies for erectile and ejaculatory dysfunction. Int J Impot Res 2000; 12: S80-S85.
3. Bechara A et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol 1997; 157: 2132-2134.
4. Fulgham PF et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998; 160: 2041-2046.
5. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60(Suppl 2): 12-27.
6. Steers W et al. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res 2001; 13: 261-267.
7. Meuleman EJ. Prevalence of erectile dysfunction: need for treatment? Int J Impot Res 2002; 14: S22-S28.
8. Carson CC. Erectile dysfunction in the 21st century: whom we can treat, whom we cannot treat and patient education. Int J Impot Res 2002; 14: S29-S34.
9. Chitaley K, Webb RC, Mills TM. The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of Rho-kinase and their potential role in the erectile response. Int J Impot Res 2003; 15: 105-109.
10. Chitaley K et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7: 119-122.
11. Rees RW et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002; 14: 1-7.
12. Rees RW et al. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 2001; 133: 455-458.
13. 2+ sensitization in erectile function. J Biol Chem 2003; 277: 30614-30621.
14. Uehata M et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994.
15. Ishizaki T et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57: 976-983.
16. Mills TM et al. Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol 2001; 91: 1269-1273.
17. Mills TM, Chitaley K, Lewis R. Vasoconstrictors in erectile physiology. Int J Impot Res 2001; 13: S29-S34.
18. Mills T et al. Endothelin-1 induced vasoconstriction is inhibited during erection in rats. Am J Physiol 2001; 281: R476-R483.
19. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522: 177-185.
20. Mills TM, Chitaley K, Lewis RW, Webb RC. Nitric oxide inhibits RhoA/Rho-kinase signaling to cause erection. Eur J Pharmacol 2002; 439: 173-174.
21. Chitaley K, Webb RC, Dorrance AM, Mills TM. Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats. Int J Impot Res 2001; 13: S16-S20.
22. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol 1997; 15: 21-26.
23. Marin R, Escrig A, Abreu P, Mas M. Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol Reprod 1999; 61: 1012-1016.
24. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J Androl 1997; 18: 110-115.
25. Reilly CM, Stopper VS, Mills TM. Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997; 18: 26-31.
26. Wingard C, Johnson J, Holmes A, Prikosh A. Improved erectile function following Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol 2003; 284: R1572-R1580.
27. Chitaley K et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun 2002; 298: 427-432.